Literature DB >> 27550400

Low-Dose Quinidine Effectively Reduced Shocks in Brugada Syndrome Patients with an Implantable Cardioverter Defibrillator: A Chinese Case Series Report.

Tongtong Shen1, Binbin Yuan2, Jie Geng1, Chun Chen1, Xiujuan Zhou1, Qijun Shan1.   

Abstract

BACKGROUND: Only implantable cardioverter defibrillators (ICD) have been proven to prevent sudden cardiac death (SCD) in patients with Brugada syndrome (BrS). However, ICD discharge, whether appropriate or inappropriate, leads to impaired quality of life and even increases rehospitalization. Quinidine might prevent the recurrence of ventricular arrhythmia (VA); however, the effect of low-dose quinidine for preventing spontaneous arrhythmias remains less clear.
METHODS: In our cardiology center, 10 confirmed patients with BrS (all men, mean age 38.7 ± 6.72 years) who underwent appropriate ICD shocks due to recurrent VAs were treated with quinidine (≤200 mg/day) and followed regularly.
RESULTS: All the patients underwent ICD shocks due to ventricular tachycardia (VT)/ventricular fibrillation (VF) before taking quinidine. A 24-hour distribution of VT/VF demonstrated that most of the events occurred in the sleeping time from 22:00 to 8:00. Quinidine prevented recurrence of VAs in nine patients. The other one patient took quinidine discontinuously because of anxiety suffered from less episodes of VA, and after psychological guidance, he took quinidine 200 mg/day and experienced no VA episodes from then on. In our series, only one patient suffered leukopenia related to quinidine. No other side effect was observed.
CONCLUSIONS: Quinidine with a very low dose (≤200 mg/day) well controlled VT/VF recurrence for a long-term period in Chinese patients with BrS. Administration (at 21:00) according to the circadian distribution of VT/VF episodes might increase the efficiency and improve the patient's tolerance.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Brugada syndrome; implantable cardioverter defibrillator; quinidine; ventricular fibrillation

Mesh:

Substances:

Year:  2016        PMID: 27550400      PMCID: PMC6931864          DOI: 10.1111/anec.12375

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  19 in total

1.  Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2.

Authors:  Frédéric Sacher; Vincent Probst; Philippe Maury; Dominique Babuty; Jacques Mansourati; Yuki Komatsu; Christelle Marquie; Antonio Rosa; Abou Diallo; Romain Cassagneau; Claire Loizeau; Raphael Martins; Michael E Field; Nicolas Derval; Shinsuke Miyazaki; Arnaud Denis; Akihiko Nogami; Philippe Ritter; Jean-Baptiste Gourraud; Sylvain Ploux; Anne Rollin; Adlane Zemmoura; Dominique Lamaison; Pierre Bordachar; Bertrand Pierre; Pierre Jaïs; Jean-Luc Pasquié; Mélèze Hocini; François Legal; Pascal Defaye; Serge Boveda; Yoshito Iesaka; Philippe Mabo; Michel Haïssaguerre
Journal:  Circulation       Date:  2013-08-30       Impact factor: 29.690

2.  ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.

Authors:  Douglas P Zipes; A John Camm; Martin Borggrefe; Alfred E Buxton; Bernard Chaitman; Martin Fromer; Gabriel Gregoratos; George Klein; Arthur J Moss; Robert J Myerburg; Silvia G Priori; Miguel A Quinones; Dan M Roden; Michael J Silka; Cynthia Tracy; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Elliott M Antman; Jeffrey L Anderson; Sharon A Hunt; Jonathan L Halperin; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Jean-Jacques Blanc; Andrzej Budaj; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano
Journal:  Circulation       Date:  2006-08-25       Impact factor: 29.690

Review 3.  Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes.

Authors:  Silvia G Priori; Arthur A Wilde; Minoru Horie; Yongkeun Cho; Elijah R Behr; Charles Berul; Nico Blom; Josep Brugada; Chern-En Chiang; Heikki Huikuri; Prince Kannankeril; Andrew Krahn; Antoine Leenhardt; Arthur Moss; Peter J Schwartz; Wataru Shimizu; Gordon Tomaselli; Cynthia Tracy; Michael Ackerman; Bernard Belhassen; N A Mark Estes; Diane Fatkin; Jonathan Kalman; Elizabeth Kaufman; Paulus Kirchhof; Eric Schulze-Bahr; Christian Wolpert; Jitendra Vohra; Marwan Refaat; Susan P Etheridge; Robert M Campbell; Edward T Martin; Swee Chye Quek
Journal:  Europace       Date:  2013-08-30       Impact factor: 5.214

Review 4.  HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.

Authors:  Silvia G Priori; Arthur A Wilde; Minoru Horie; Yongkeun Cho; Elijah R Behr; Charles Berul; Nico Blom; Josep Brugada; Chern-En Chiang; Heikki Huikuri; Prince Kannankeril; Andrew Krahn; Antoine Leenhardt; Arthur Moss; Peter J Schwartz; Wataru Shimizu; Gordon Tomaselli; Cynthia Tracy
Journal:  Heart Rhythm       Date:  2013-08-30       Impact factor: 6.343

Review 5.  Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review.

Authors:  Manlio F Márquez; Aimé Bonny; Eduardo Hernández-Castillo; Antonio De Sisti; Jorge Gómez-Flores; Santiago Nava; Françoise Hidden-Lucet; Pedro Iturralde; Manuel Cárdenas; Joelci Tonet
Journal:  Heart Rhythm       Date:  2012-08-28       Impact factor: 6.343

6.  The healthcare utilization and cost of treating patients experiencing inappropriate implantable cardioverter defibrillator shocks: a propensity score study.

Authors:  Sanjeev P Bhavnani; Dalia Giedrimiene; Craig I Coleman; Danette Guertin; Meena Azeem; Jeffrey Kluger
Journal:  Pacing Clin Electrophysiol       Date:  2014-08-19       Impact factor: 1.976

7.  Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome.

Authors:  B Belhassen; S Viskin; R Fish; A Glick; I Setbon; M Eldar
Journal:  J Cardiovasc Electrophysiol       Date:  1999-10

8.  Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine.

Authors:  Abdeslam Bouzeman; Sarah Traulle; Anne Messali; Fabrice Extramiana; Isabelle Denjoy; Kumar Narayanan; Eloi Marijon; Jean-Sylvain Hermida; Antoine Leenhardt
Journal:  Europace       Date:  2013-09-25       Impact factor: 5.214

9.  Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation.

Authors:  Takeshi Ohgo; Hideo Okamura; Takashi Noda; Kazuhiro Satomi; Kazuhiro Suyama; Takashi Kurita; Naohiko Aihara; Shiro Kamakura; Tohru Ohe; Wataru Shimizu
Journal:  Heart Rhythm       Date:  2007-02-20       Impact factor: 6.343

10.  Near fatal ventricular fibrillation in Brugada syndrome despite presence of an implanted implantable cardioverter defibrillator.

Authors:  Bernard Belhassen; Sami Viskin
Journal:  Can J Cardiol       Date:  2014-06-27       Impact factor: 5.223

View more
  1 in total

1.  Low-Dose Quinidine Effectively Reduced Shocks in Brugada Syndrome Patients with an Implantable Cardioverter Defibrillator: A Chinese Case Series Report.

Authors:  Tongtong Shen; Binbin Yuan; Jie Geng; Chun Chen; Xiujuan Zhou; Qijun Shan
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-08-23       Impact factor: 1.468

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.